Sanofi's Multaq hits another setback
This article was originally published in Scrip
Sanofi has halted the Phase IIIb PALLAS study of its anti-arrhythmic Multaq (dronedarone) in the additional treatment setting of permanent atrial fibrillation (AF) on safety concerns.
You may also be interested in...
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.
Just over a year ago, AstraZeneca at last returned to growth and set about a reorganization that placed oncology at the heart of its plans for continued success. In Vivo talked to the executive vice-president of its Oncology Business Unit David Fredrickson about how the company hopes to become a major cancer player.